International Conference on Cell Therapy and Tissue Engineering:
Regenerative Medicine - New Developments
on 8th-9th June 2016 in Tallinn, Estonia
What is regenerative medicine (RM) and why many consider it a way out of the puzzled present and into the promising future of medicine? RM is a discipline that does nothing else but stimulates human body´s capability to cure and heal itself. Human body has taken care of itself during several thousand years, but in some instances it fails. The aim of RM is to give a helping hand in these instances.
What is already possible today and in the coming future? What is RM capable of doing today and which direction should it take tomorrow? If we have a brilliant idea, to whom should we forward it in order to be successful and where to find an investor? Should legislation regulate the evolution of RM and if yes, in which way? Based on today´s knowledge of RM - what seems as a hope and what as a hype? How should venture capitalists (risk investors) recognize a fruitful idea and distinguish it from a scam?
In August 2015 in Tallinn we heard presentations about the controversies and challenges in RM from scientists and specialists from Europe and United States of America. Among foreign presenters were N.E.Vrana (France), J.Boltze (Germany), A.Y.Nosset (Netherlands), K.March (US), A.Darinskas (Lithuania), K.K.Kleinhenz (US), G. Lintjens (Netherlands), P.Salmikangas (Finland).
Presented topics covered areas from immunomodulation, brain repair strategies, cancer vaccins, vascular remodeling, vasculogenesis and osteoarthritis treatment to ways of how patients can get access to medical products still in development. We also heard about the legal regulatory perspectives of RM and risk investors opinion about the attractiveness of investing in RM.
In June 2016 in we start seeking answers to questions of new developments, like how many clinical bases all over Europe and America have already started using methods of RM, and exactly which methods. What we can do already today and what we can do within next years?
As a newly adopted tradition Estonian Cell Therapy Cluster and Estonian Regenerative Medicine Association are organizing the 2016 Conference. World´s leading experts in research, clinical medicine and legal regulations, as well Estonian specialists, will present their opinion and viewpoints.
Such names like Ralf Sanzenbacher, Paula Salmikangas, Dariusz Sladowski, Jaan Feldmann, Hele Everaus, Andrus Loog and Toivo Maimets are few of the experts stepping up with their presentations in the conference.
The two pillars of RM, cell therapy and tissue engineering, may play even a more essential role in the future than gene technology plays today in the sense of personalized medicine.
Autologous cell therapy, as one of the branches of RM, represents personalized medicine in its most pure and essential way. It means that the donor and recipient lay in the same human body.
In order to be successful in RM, all involved parties in the process must cooperate:
clinicians, who are worried about the dead-end-situation in today´s conventional treatment methods, with researchers, who develop cell therapy, with regulators, who are confused whether cell therapy should be considered a new drug in use or simply a new treatment option. And with back-up forces like pharmaceutical companies, IT specialists, venture capitalists, who support the process. We can´t be successful, if those four parties won`t speak to each other in one auditorium.
The Conference in Tallinn is one of the attempts to bring those four parties together around one table. But we can´t go too much into specific details - it is the first complex approach, where we attempt to stay understandable to different parties around the table. Only after finding common ground among the parties can we dig deeper and thus become more detail-specific.
Who are the broader target groups we expect to see sitting in the auditorium and listen?
1. Medical Clinicians, who want to find new treatment modalities, because today´s conventional methods don´t help their patients enough. Who should they approach with some of their new ideas? Mostly all new ideas be down regulated by the National Drug Administration Committee? How can we spare innovation from the bureaucratic regulations?
2. Researchers, who want to find a more precise focus for their research projects. What regulatory instruments will help them and which will block their activities? Where to find financial investors? Is there a need on the market for their projects (results)?
3. Regulators, who sit among different Ministries and Drug Administration Committees. How strongly should RM be regulated? How decision-making-bureaucracy can favor new inventions of RM?
4. Back-up-forces. How should pharmaceutical companies, IT specialists, venture capitalists etc. behave, when they see a new biotechnological "bubble" getting started? How IT knowledge can be used to protect interests of the patients?
Please register in the following link: http://goo.gl/forms/aSI3gMmnG0
The fees are following:
Until 30th April 2016 159 euros (Student, residents 119 euros);
Until 6th June 2016 199 euros (Student, residents 149 euros);
7th-8th June 2016 259 euros.
Registration fee includes two days of participation, conference materials via internet, coffee breaks and lunches.
Conference will take place at Nordic Hotel Forum in Tallinn (Viru väljak 3, phone 622 2900).